HIGHLIGHTS
- who: Quoc Thang Bui et al. from the Taipei University, Taipei, Taiwan have published the research work: Disruption of CCL2 in Mesenchymal Stem Cells as an Anti-Tumor Approach against Prostate Cancer, in the Journal: Cancers 2023, 15, x FOR PEER REVIEW of 16/Oct/2018
- what: Genetically engineered MSCs with CCL2 knockout can enhance the anti-tumor effect in an immune-competent syngeneic mouse model of prostate cancer.
- how: To secure the abundance and consistency of MSCs for further investigation the authors used commercially available mouse bone marrow-derived MSCs and confirmed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.